GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » YoY EBITDA Growth

EirGenix (ROCO:6589) YoY EBITDA Growth : -6.82% (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is EirGenix YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. EirGenix's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was -6.82%.

EirGenix's EBITDA per Share for the three months ended in Jun. 2024 was NT$-0.47.

EirGenix YoY EBITDA Growth Historical Data

The historical data trend for EirGenix's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EirGenix YoY EBITDA Growth Chart

EirGenix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -78.66 4.33 116.36 -51.18 -756.33

EirGenix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -340.44 -284.62 -559.88 80.00 -6.82

EirGenix YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

EirGenix's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-2.179-0.332)/ | 0.332 |
=-756.33 %

EirGenix's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(-0.47--0.44)/ | -0.44 |
=-6.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EirGenix YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of EirGenix's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

EirGenix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EirGenix Inc (ROCO:6589) » Definitions » YoY EBITDA Growth
Comparable Companies
ROCO:6547 ROCO:6919 ROCO:4147 ROCO:6617 ROCO:4174 ROCO:6976 ROCO:4162 ROCO:6712 ROCO:6586 TPE:4142 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
Website
https://www.eirgenix.com
EirGenix Inc is engaged in biosimilar and new drug research and development as well as biopharmaceutical contract development and manufacturing services, including cell line construction platforms, process development platforms, analytical science and protein characterisation, as well as PIC/S facilities to provide clinical trial drug production. Its services include Cell Line Development, Process Development, Analytical Science and Quality Control, cGMP manufacturing-mammalian system, cGMP manufacturing-microbial system, and Antibody Drug Conjugate.

EirGenix Headlines

No Headlines